TNFRSF4 and myeloid sarcoma: Globally, CD134 expression on CD4+ T-cells was not significantly different in untreated and natalizumab-treated MS-patients (data not shown), but the percentage of CD26HIGHCD4+ T-cells which expressed CD134 was significantly lower in natalizumab-treated than in untreated MS patients (Figure 4E).